Intellia Therapeutics

Intellia Therapeutics Announces First Patient Dosed in the Phase 3 MAGNITUDE Study of NTLA-2001 as a Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with Cardiomyopathy

Retrieved on: 
Monday, March 18, 2024
Pharmacology, Royal Free Hospital, NTLA, Disease, TTR, Richmond Pharmacology, Patient, Amyloidosis, Cardiomyopathy, Intellia Therapeutics, Heart failure, Therapy, CRISPR, Safety, Phase 1, ATTR, Pharmaceutical industry

NTLA-2001 is an investigational in vivo CRISPR-based therapy designed as a single-dose treatment to inactivate the TTR gene and thereby prevent the production of TTR protein for the treatment of transthyretin (ATTR) amyloidosis.

Key Points: 
  • NTLA-2001 is an investigational in vivo CRISPR-based therapy designed as a single-dose treatment to inactivate the TTR gene and thereby prevent the production of TTR protein for the treatment of transthyretin (ATTR) amyloidosis.
  • The MAGNITUDE trial is evaluating the efficacy and safety of NTLA-2001 in patients with ATTR amyloidosis with cardiomyopathy.
  • We look forward to evaluating the efficacy and safety of NTLA-2001 in patients with cardiomyopathy in the pivotal Phase 3 trial.
  • There is remarkable interest from the ATTR amyloidosis patient community for a potential single-dose treatment, and we look forward to contributing to the advancement of novel treatment approaches.”

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Company Progress

Retrieved on: 
Thursday, February 22, 2024
Research, Intellia Therapeutics, Regeneron Pharmaceuticals, Fatigue, Haemophilia, NK, CTA, Liver, Cystic fibrosis, ATM, A1AT, Amyloidosis, HAE, Therapy, European Medicines Agency, ATTR, Haemophilia B, DNA, European Commission, Hereditary angioedema, Recode, Conference, Cardiomyopathy, AATD, Civil service commission, Clinical trial, Facial muscles, CRISPR, Gene editing, Food, NTLA, KLKB1, Lung, NEJM, TTR, Patient, Medicine, Disease, Tissue, Pharmaceutical industry

Collaboration Revenue: Collaboration revenue decreased by $15.5 million to negative $1.9 million during the fourth quarter of 2023, compared to $13.6 million during the fourth quarter of 2022.

Key Points: 
  • Collaboration Revenue: Collaboration revenue decreased by $15.5 million to negative $1.9 million during the fourth quarter of 2023, compared to $13.6 million during the fourth quarter of 2022.
  • R&D Expenses: Research and development expenses increased by $9.0 million to $109.0 million during the fourth quarter of 2023, compared to $100.0 million during the fourth quarter of 2022.
  • G&A Expenses: General and administrative expenses increased by $5.4 million to $29.0 million during the fourth quarter of 2023, compared to $23.6 million during the fourth quarter of 2022.
  • Net Loss: The Company’s net loss was $132.2 million for the fourth quarter of 2023, compared to $113.4 million during the fourth quarter of 2022.

Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis

Retrieved on: 
Thursday, February 15, 2024
Therapy, LNP, Liver, MB, CRISPR, Gene editing, Messenger, Intellia Therapeutics, Recode, Cystic fibrosis, Mucus, NTLA, Lung, DSM-IV codes, Respiratory failure, Cell, CFTR, Patient, Medicine, Tissue, Research, DNA, Vaccine

and MENLO PARK, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, and ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, today announced a strategic collaboration to develop novel genomic medicines for the treatment of cystic fibrosis (CF).

Key Points: 
  • and MENLO PARK, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, and ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, today announced a strategic collaboration to develop novel genomic medicines for the treatment of cystic fibrosis (CF).
  • Intellia will be responsible for the design of the editing strategy and research-grade components for the investigational therapies.
  • “This collaboration provides further validation of ReCode's SORT LNP platform to deliver diverse gene editing modalities to specific cells and tissues.
  • By combining our highly synergistic technologies and capabilities, we are excited about the potential to enable a faster path for next-generation gene editing therapeutics to CF patients.”

Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis

Retrieved on: 
Thursday, February 15, 2024
Health, Genetics, Other Science, Research, Science, Biotechnology, Therapy, LNP, Liver, MB, CRISPR, Gene editing, Intellia Therapeutics, Messenger, Recode, Cystic fibrosis, Mucus, NTLA, DSM-IV codes, Respiratory failure, Cell, CFTR, Patient, Medicine, Tissue, DNA, Vaccine

Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, and ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, today announced a strategic collaboration to develop novel genomic medicines for the treatment of cystic fibrosis (CF).

Key Points: 
  • Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, and ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, today announced a strategic collaboration to develop novel genomic medicines for the treatment of cystic fibrosis (CF).
  • Intellia will be responsible for the design of the editing strategy and research-grade components for the investigational therapies.
  • “This collaboration provides further validation of ReCode's SORT LNP platform to deliver diverse gene editing modalities to specific cells and tissues.
  • By combining our highly synergistic technologies and capabilities, we are excited about the potential to enable a faster path for next-generation gene editing therapeutics to CF patients.”

Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2023 Earnings and Company Updates

Retrieved on: 
Wednesday, February 14, 2024
Medicine, NTLA, Therapy, CRISPR, Intellia Therapeutics

CAMBRIDGE, Mass., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, will present its fourth quarter and full-year 2023 financial results and operational highlights in a conference call on February 22, 2024, at 8 a.m.

Key Points: 
  • CAMBRIDGE, Mass., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, will present its fourth quarter and full-year 2023 financial results and operational highlights in a conference call on February 22, 2024, at 8 a.m.
  • U.S. callers should dial 1-833-316-0545 and international callers should dial 1-412-317-5726, approximately five minutes before the call.
  • All participants should ask to be connected to the Intellia Therapeutics conference call.
  • Please visit this link for a simultaneous live webcast of the call.

Global Genome Editing Market Research Report 2023-2035: Pharmaceutical Giants Expand Capabilities - WuXi AppTec and Ensoma Lead Acquisitions - ResearchAndMarkets.com

Retrieved on: 
Monday, February 12, 2024
Health, Genetics, Acquisition, Wuxi, Regenerative medicine, CRISPR, WuXi AppTec, Gene editing, Intellia Therapeutics, Research, Cas9, Drug discovery, Mammoth Biosciences, Genetic engineering, Safety, Therapy, Genome, Horizon Discovery, Genomics, Antibiotics

The "Global Genome Editing Market, 2023-2035: Focus on Technology, Industry Trends and Forecasts" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Genome Editing Market, 2023-2035: Focus on Technology, Industry Trends and Forecasts" report has been added to ResearchAndMarkets.com's offering.
  • The report features an extensive study of the current market landscape, market size and future opportunities associated with the genome editing market, during the given forecast period.
  • Further, the genome editing market report highlights the efforts of several stakeholders engaged in this rapidly emerging segment of the pharmaceutical industry.
  • The genome editing market landscape is concentrated with the presence of over 110 genome editing companies (very large, large, mid-sized and small companies).

Genome Editing Market Report 2024: Technology Licensing Deals are Driving the Overall Partnership Activity - Global Industry Trends and Forecasts 2023-2035

Retrieved on: 
Wednesday, February 7, 2024
Genomics, Genetic engineering, Mammoth Biosciences, Regenerative medicine, Gene editing, Research, Horizon Discovery, Safety, Wuxi, Drug discovery, Intellia Therapeutics, Therapy, Acquisition, Cas9, CRISPR, WuXi AppTec, Genome, Antibiotics

DUBLIN, Feb. 7, 2024 /PRNewswire/ -- The "Global Genome Editing Market, 2023-2035: Focus on Technology, Industry Trends and Forecasts" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Feb. 7, 2024 /PRNewswire/ -- The "Global Genome Editing Market, 2023-2035: Focus on Technology, Industry Trends and Forecasts" report has been added to ResearchAndMarkets.com's offering.
  • The report features an extensive study of the current market landscape, market size and future opportunities associated with the genome editing market, during the given forecast period.
  • Further, the genome editing market report highlights the efforts of several stakeholders engaged in this rapidly emerging segment of the pharmaceutical industry.
  • The genome editing market landscape is concentrated with the presence of over 110 genome editing companies (very large, large, mid-sized and small companies).

Intellia Therapeutics Announces Publication of Positive Interim Phase 1 Data for NTLA-2002 in Patients with Hereditary Angioedema in the New England Journal of Medicine

Retrieved on: 
Wednesday, January 31, 2024
Anxiety, Angioedema, Hereditary angioedema, NTLA, Patient, HAE, Intellia Therapeutics, Therapy, CRISPR, Medicine, NEJM, Fatigue, Pharmaceutical industry

“Despite currently available treatments, people living with hereditary angioedema continue to face frequent anxiety about their next swelling attack.

Key Points: 
  • “Despite currently available treatments, people living with hereditary angioedema continue to face frequent anxiety about their next swelling attack.
  • The interim NTLA-2002 clinical data published suggest that a single dose of NTLA-2002 may eliminate angioedema attacks for people suffering from hereditary angioedema,” said Intellia President and Chief Executive Officer John Leonard, M.D.
  • Further, all patients who discontinued concomitant long-term HAE prophylaxis treatment after NTLA-2002 administration (n=6) have reported no HAE attacks since discontinuation.
  • The data were previously shared in a late-breaking presentation at the 2023 European Academy of Allergy and Clinical Immunology Hybrid Congress.

San Francisco Witnesses the Voice of GCT Titans GenScript Biotech Global Forum Outlines the Future of the Industry

Retrieved on: 
Friday, January 12, 2024
Stanford University, DSM-IV codes, Overalls, Gene therapy, Flagship Pioneering, Biotechnology, Artificial intelligence, Neogene, CBER, Gene editing, Genome editing, Assistant professor, Therapy, Biological engineering, SAN, Humour, Harvard University, GenScript Biotech, Optimism, Safety, Patient, J. P. Morgan, AstraZeneca, Hope, GCT, Broad Institute, CBO, Process, Animal, Gene, ARCH Venture Partners, Multiple myeloma, Speech, Intellia Therapeutics, Development, Associate, Health, CRISPR, Intelligence, Courage, Research and development, Division, Conference, T cell, FDA, Eli Lilly and Company, SVP, Pharmaceutical industry

On January 10 this year, GenScript Biotech hosted the "Satellite Session" of the J.P. Morgan annual conference—the 2024 GenScript Biotech Global Forum in San Francisco.

Key Points: 
  • On January 10 this year, GenScript Biotech hosted the "Satellite Session" of the J.P. Morgan annual conference—the 2024 GenScript Biotech Global Forum in San Francisco.
  • GenScript Biotech is committed to building a high-quality platform for exchange and cooperation for global peers, driving the advancement of the cell and gene industry.
  • since the first global forum was held in 2020, GenScript Biotech has created numerous valuable opportunities for industry peers.
  • This grand event brought together the wisdom and strength of global elites in the biopharmaceutical industry, sparking a profound discourse on the future of GCT.

Intellia Therapeutics Highlights its Three-Year Strategic Priorities and Anticipated 2024 Key Milestones

Retrieved on: 
Thursday, January 4, 2024
Liver, Conference, Science, Gene editing, Biotechnology Innovation Organization, Amyloidosis, BIO, CRISPR, Phase 1, Tissue, DNA, Cardiomyopathy, Therapy, ATTR, Intellia Therapeutics, NTLA, Clinical trial, Polyneuropathy, NK, AATD, Lung, Hereditary angioedema, Webcast, Patient, Medicine, HAE, BLA, Pharmaceutical industry

Organizational Streamlining: Following an internal strategic review, Intellia will be streamlining company-wide operations to further focus resources on key strategic priorities and programs.

Key Points: 
  • Organizational Streamlining: Following an internal strategic review, Intellia will be streamlining company-wide operations to further focus resources on key strategic priorities and programs.
  • Cash Runway: Intellia ended the fourth quarter of 2023 with approximately $1.0 billion in cash, cash equivalents and marketable securities.
  • Prepare for the Phase 3 study of NTLA-2001 for the treatment of ATTR amyloidosis with polyneuropathy (ATTRv-PN) in 2024.
  • A live webcast will be available through the Events and Presentations page of the Investors & Media section on Intellia’s website, www.intelliatx.com .